Drugs / Bifidobacterium probiotics supplementation
Bifidobacterium probiotics supplementation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07206303 | May 2026 → May 2027 expected | hypertensive disorder | The University of Hong Kong | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium probiotics supplementation | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07206303 ↗ |
| Modality | Other / unclassified | “Bifidobacterium-based probiotic intervention” NCT07206303 ↗ |
| Route | Oral | “oral administration of Bifidobacterium-based probiotic intervention” NCT07206303 ↗ |